Swiss healthcare giant Roche is advancing prasinezumab, a potential first-in-class anti-alpha-synuclein antibody for early Parkinson’s disease, into Phase III trials. This decision follows encouraging data from the Phase IIb PADOVA study and its long-term follow-up, suggesting the drug offers clinical benefits.

Amino acids are the basic structural units of proteins, which are critical macromolecules of all living organisms. Proteins play a role in almost every aspect of biological function, and structure and function are conferred by the sequence and nature of amino acids. Read the detailed description of amino acids. Structure […]